NYSE:NVTA - Invitae Stock Price, Price Target & More

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Invitae (NYSE:NVTA) announced its earnings results on Wednesday, May, 9th. The medical research company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.61) by $0.05. The medical research company earned $27.67 million during the quarter, compared to the consensus estimate of $26.86 million. Invitae had a negative net margin of 154.96% and a negative return on equity of 127.38%. The business's quarterly revenue was up 167.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.64) EPS. View Invitae's Earnings History.

Invitae is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Invitae.

4 Wall Street analysts have issued 12 month price objectives for Invitae's shares. Their predictions range from $9.00 to $15.00. On average, they expect Invitae's stock price to reach $11.00 in the next year. View Analyst Ratings for Invitae.

Some companies that are related to Invitae include Genomic Health (GHDX), Natera (NTRA), RadNet (RDNT), CareDx (CDNA), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Veracyte (VCYT), Celcuity (CELC), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), Biocept (BIOC), OpGen (OPGN) and Cord Blood America (CBAI).

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Media coverage about NVTA stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Invitae earned a coverage optimism score of 0.16 on Accern's scale. They also gave news headlines about the medical research company an impact score of 46.98 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Invitae's stock is owned by many different of institutional and retail investors. Top institutional investors include ARK INVESTMENT MANAGEMENT LLC (10.84%), WELLINGTON MANAGEMENT PORTFOLIOS (DUBLIN) PUBLIC LTD COMPANY (5.23%), BlackRock Inc. (5.15%), Redmile Group LLC (3.18%), Rock Springs Capital Management LP (2.08%) and CVI Holdings LLC (0.67%). Company insiders that own Invitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Institutional Ownership Trends for Invitae.

NVTA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Redmile Group LLC and Schwab Charles Investment Management Inc.. Company insiders that have sold Invitae company stock in the last year include E Lee Bendekgey, Katherine Stueland, Patty Dumond, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Insider Buying and Selling for Invitae.

NVTA stock was purchased by a variety of institutional investors in the last quarter, including CVI Holdings LLC, BlackRock Inc., Victory Capital Management Inc., Rock Springs Capital Management LP, Blair William & Co. IL, Dimensional Fund Advisors LP, Gamco Investors INC. ET AL and Teton Advisors Inc.. Company insiders that have bought Invitae stock in the last two years include Bros Advisors Lp Baker, Geoffrey Crouse and Randal W Scott. View Insider Buying and Selling for Invitae.

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NVTA stock can currently be purchased for approximately $7.63.

Invitae has a market capitalization of $486.56 million and generates $68.22 million in revenue each year. The medical research company earns $-123,380,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. Invitae employs 594 workers across the globe.

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]